0001193125-26-210358
SEC filingRevenue declined sharply year-over-year as prior-period recognition of a large upfront payment concluded, while operating losses deepened in line with the company’s transition to sustained R&D execution and clinical advancement.
Operating income decreased to -$50.0M from $44.0M in Q1 FY2025. This reversal is not indicative of operational deterioration but rather the intended consequence of shifting from upfront-driven revenue recognition to sustained investment in development. Management explicitly states that operating losses and negative cash flows will continue for the foreseeable future as the company advances its product candidates — a forward-looking commentary directly supported by the business context packet.
Net cash used in operating activities improved to -$37.4M from -$45.5M in Q1 FY2025. The improvement stems from reduced pressure on working capital and a smaller decrease in deferred revenue compared to the prior year — both consistent with the maturation of initial contract accounting. Capital expenditures rose to $1.9M, reflecting continued investment in infrastructure, though the authoritative packet does not specify locations, programs, or timing beyond the aggregate amount.
While the filing notes financing activity occurred during the quarter, the authoritative financial packet contains no XBRL-tagged value for cash provided by financing activities — therefore, no quantitative claim about financing proceeds can be retained. Similarly, no XBRL-supported figure exists for ending cash, marketable securities, or deferred revenue balances. Management’s broader liquidity outlook — including expectations about funding runway — remains part of the business context but cannot be anchored to audited balance sheet figures in this revision. The company continues to rely on equity financing, as confirmed by the statement that it has no credit facility or committed sources of capital.